Inhibitor of Apoptosis Proteins (IAP) Antagonists Market: Competitive Landscape, Pipeline, and Market Analysis 2023

Purchase Option

$ 4400
$ 6600
$ 8900

Inhibitor of Apoptosis Proteins (IAP) are a family of functionally and structurally related proteins which serve as endogenous inhibitors of programmed cell death, by blocking caspases proteins, which could lead to cancer or other effects on the cell if mutated or improperly regulated. IAPs are characterized by the presence of one or more BIR (Baculovirus IAP Repeated) domains, which is essential for the anti-apoptotic activity of IAPs as it is required for caspase binding. IAP antagonists promote cancer cell death by inhibiting IAPs. The drug molecules for IAP antagonists are in clinical trials for colorectal cancer, non-Hodgkin’s lymphoma, ovarian cancer, solid tumors, pancreatic cancer, hepatitis B, and others. Pharmaceutical companies such as Novartis, Roche, Eli Lilly, AbbVie, BeiGene, Boehringer Ingelheim, and others are doing clinical studies for IAP antagonists.

Key Market Developments:

  • In Mar 2022, Cothera Bioscience received approval from the National Medical Products Administration (NMPA) for a phase-II trial in B-cell lymphoma patients for Sepantronium-Bromide (PC002).
  • In Jul 2022, NexImmune announced IND clearance by the US FDA for NEXI 003, an autologous antigen-specific T cell product for the treatment of HPV-related cancers.

Drugs under the Pipeline for Inhibitor of Apoptosis Proteins (IAP) Antagonistss:

  • Birinapant (IGM-9427)
  • Xevinapant (Debio 1143)
  • Maveropepimut-S (MVP-S)
  • Sepantronium bromide (PC-002)
  • GEM 640
  • LCL161
  • SurVaxM (SVN53-67/M57-KLH peptide vaccine)
  • Veyonda (Idronoxil)
  • Tolinapant (ASTX660)
  • Phenoxodiol (NV06)
  • APG-1387
  • CINelim (Terameprocol)
  • MultiTAA T cell therapy
  • Gataparsen (LY2181308)
  • AEG40826
  • BI 891065
  • CUDC-427
  • IO101
  • MT-601
  • SL-701
  • TQB3728
  • ABBV-184
  • BGB-24714
  • GDC0152
  • MANA-312
  • NEXI-003
  • OVM-200
  • PDC*lung01
  • Antisense LNA (EZN-3042) 

Clinical Activity and Developments of Inhibitor of Apoptosis Proteins (IAP) Antagonists:

Currently, there are about 34 drug molecules in clinical trial phases as inhibitors of apoptosis for various cancers.

  • In Nov 2022, Ascentage Pharma Group completed a phase-I trial in haematological malignancies and solid tumors in the USA for APG1387, an inhibitor of apoptosis.
  • In May 2022, M.D. Anderson Cancer Center in collaboration with the National Cancer Institute and Novartis Pharmaceuticals completed a phase-II trial in Myelofibrosis patients in the USA for LCL161, a second mitochondria activator of caspases (SMAC) mimetic.

Molecule Name

Number of Studies

Birinapant (IGM-9427)

15

Xevinapant (Debio 1143)

15

Maveropepimut-S (MVP-S)

14

Sepantronium bromide (PC-002)

12

GEM 640

10

LCL161

10

SurVaxM (SVN53-67/M57-KLH peptide vaccine)

10

Veyonda (Idronoxil)

10

Tolinapant (ASTX660)

9

Phenoxodiol (NV06)

7

APG-1387

6

CINelim (Terameprocol)

6

MultiTAA T cell therapy

4

Gataparsen (LY2181308)

4

AEG40826

2

BI 891065

2

CUDC-427

2

IO101

2

MT-601

2

SL-701

2

TQB3728

2

ABBV-184

1

BGB-24714

1

GDC0152

1

MANA-312

1

NEXI-003

1

OVM-200

1

PDC*lung01

1

Antisense LNA (EZN-3042)

1

Target Indication Analysis of Inhibitor of Apoptosis Proteins (IAP) Antagonists

At present, IAP antagonists are in clinical trial phases, such as Medivir AB’s Birinapant is in phase-I for non-Hodgkin’s lymphoma, in phase-I/II for acute myeloid leukaemia, and hepatitis B, and in phase-II for chronic myelomonocytic leukaemia, colorectal cancer, myelodysplastic syndromes, ovarian cancer, and solod tumors. Similarly, Debiopharm’s Xevinapant is in phase-I for adenocarcinoma, colorectal cancer, non-small cell lung cancer, in phase-II for ovarian cancer, and solid tumors, and in phase-III for squamous cell cancer. Additionally, IMV’s Maveropepimut S is in phase-I for breast cancer, phase-I/II for solid tumors, and in phase-II for bladder cancer, diffuse large B cell lymphoma, fallopian tube cancer, glioblastoma, liver cancer, non-small cell lung cancer, ovarian cancer, peritoneal cancer, and urogenital cancer.

Frequently Asked Questions

Birinapant (IGM-9427), Xevinapant (Debio 1143), Maveropepimut-S (MVP-S), and Sepantronium bromide (PC-002) are some of the drugs under pipeline in the Inhibitor of Apoptosis Proteins (IAP) antagonists.

Novartis, Roche, Eli Lilly, AbbVie, BeiGene, and Boehringer Ingelheim are some of the major market players in the Inhibitor of Apoptosis Proteins (IAP) antagonists.

Major indications for Inhibitor of Apoptosis Proteins (IAP) Antagonistss are colorectal cancer, non-Hodgkin’s lymphoma, ovarian cancer, solid tumors, pancreatic cancer, and hepatitis B.

There are a total of 32 molecules in the Phase-I/II clinical development for Inhibitor of Apoptosis Proteins (IAP) Antagonists.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • Novartis AG (Switzerland)
  • IGM Biosciences (USA)
  • IMV Inc (USA)
  • Cothera Bioscience (China)
  • Noxopharm (Australia)
  • Otsuka Pharmaceutical (Japan)
  • Ascentage Pharma (Japan)
  • Erimos Pharmaceuticals (USA)
  • Eli Lilly and Company (USA)
  • Boehringer Ingelheim (Germany)
  • Roche (USA)
  • Marker Therapeutics (USA)
  • Sino Biopharm (China)
  • AbbVie (USA)
  • BeiGene (USA)
  • NexImmune (USA)

Adjacent Markets